{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:56:12Z","timestamp":1793382972278,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ijantimicag.2024.107396","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T16:48:13Z","timestamp":1732812493000},"page":"107396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["HIV-1 viral decay in blood and semen in antiretroviral-na\u00efve adults initiating dolutegravir\/lamivudine vs. bictegravir\/emtricitabine\/tenofovir alafenamide"],"prefix":"10.1016","volume":"65","author":[{"given":"Yongjian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyun","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyi","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3917-3027","authenticated-orcid":false,"given":"Lili","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2024.107396_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2023.08.006","article-title":"Spontaneous HIV expression during suppressive ART is associated with the magnitude and function of HIV-specific CD4+ and CD8+ T cells","volume":"31","author":"Dub\u00e9","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0002","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1086\/605578","article-title":"Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy","volume":"49","author":"Ross","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0003","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001888","article-title":"Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission","volume":"3","author":"Baeten","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0004","first-page":"E01","article-title":"Society of Infectious Diseases, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection\/acquired immunodeficiency syndrome (2024 edition)","volume":"42","year":"2024","journal-title":"Chin J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0005","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. 2024. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/adult-adolescent-arv\/guidelines-adult-adolescent-arv.pdf (accessed April 19, 2024)."},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 Recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"Gandhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0007","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0008","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1007\/s40121-023-00879-x","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide versus dolutegravir plus lamivudine for switch therapy in patients with HIV-1 infection: A real-world cohort study","volume":"12","author":"Gan","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0009","doi-asserted-by":"crossref","first-page":"ofac068","DOI":"10.1093\/ofid\/ofac068","article-title":"Changes in inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in antiretroviral therapy-experienced, virologically suppressed people with HIV-1: A systematic literature review","volume":"9","author":"Llibre","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0010","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/infdis\/jiw406","article-title":"HIV-1-RNA decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen","volume":"214","author":"Imaz","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0011","doi-asserted-by":"crossref","first-page":"e1991","DOI":"10.1093\/cid\/ciaa1416","volume":"73","author":"Imaz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0012","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/cid\/ciw784","article-title":"Longitudinal viral dynamics in semen during early HIV infection","volume":"64","author":"Morris","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0013","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/infdis\/jiad304","article-title":"Decay of HIV RNA in seminal plasma and rectal fluid in treatment-naive adults starting antiretroviral therapy with dolutegravir plus lamivudine or bictegravir\/emtricitabine\/tenofovir alafenamide","volume":"228","author":"Sc\u00e9vola","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0014","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/jac\/dkad245","article-title":"Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir\/lamivudine versus dolutegravir plus emtricitabine\/tenofovir alafenamide in treatment-naive people living with HIV","volume":"78","author":"Saborido-Alconchel","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1279390","article-title":"Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG\/3TC vs. B\/F\/TAF: the DEBATE trial","volume":"14","author":"Cossarizza","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0016","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/QAI.0000000000003395","article-title":"Durable efficacy of switching from a 3- or 4-drug tenofovir alafenamide\u2013based regimen to the 2-drug regimen dolutegravir\/lamivudine in the TANGO study through week 196","volume":"96","author":"De Wit","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0017","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0018","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0019","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/COH.0000000000000287","article-title":"Persistent HIV-1 replication during antiretroviral therapy","volume":"11","author":"Martinez-Picado","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-1-0716-1871-4_13","article-title":"More than a gender issue: Testis as a distinctive HIV Reservoir and its implication for viral eradication","volume":"2407","author":"Routy","year":"2022","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0021","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00755-19","article-title":"HIV diversity and genetic compartmentalization in blood and testes during suppressive antiretroviral therapy","volume":"93","author":"Miller","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0022","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1097\/QAD.0b013e3283303e04","article-title":"Persistent HIV RNA shedding in semen despite effective antiretroviral therapy","volume":"23","author":"Sheth","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12985-020-01300-6","article-title":"Detectable HIV-1 in semen in individuals with very low blood viral loads","volume":"17","author":"Kariuki","year":"2020","journal-title":"Virol J"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0024","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/infdis\/jiad520","article-title":"Viral load dynamics in plasma and semen when antiretroviral therapy is initiated during early HIV-1 infection","volume":"229","author":"Gilada","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0025","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/jac\/dkaa035","article-title":"Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir\u2009+\u2009lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial)","volume":"75","author":"Charpentier","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0026","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1097\/QAD.0b013e328353b11b","article-title":"Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men","volume":"26","author":"Politch","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0027","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/infdis\/jiab336","article-title":"HIV-1 RNA kinetics in blood plasma and in seminal plasma of men starting a dolutegravir-based triple-combination regimen at the time of primary HIV-1 infection","volume":"225","author":"Ghosn","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0028","doi-asserted-by":"crossref","first-page":"e23063","DOI":"10.1097\/MD.0000000000023063","article-title":"HIV-1 diversity and compartmentalization in urine, semen, and blood","volume":"99","author":"Stadtler","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0029","doi-asserted-by":"crossref","first-page":"e2000","DOI":"10.1093\/cid\/ciaa1529","article-title":"Effects of urethritis on human immunodeficiency virus (HIV) in semen: Implications for HIV prevention and cure","volume":"73","author":"Chen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1186\/s12879-017-2676-2","article-title":"Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns","volume":"17","author":"Falasca","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0031","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/17512433.2019.1605902","article-title":"Does choice of antiretroviral drugs matter for inflammation?","volume":"12","author":"Gutierrez","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0032","series-title":"Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation","author":"Serrano Villar","year":"2020"},{"key":"10.1016\/j.ijantimicag.2024.107396_bib0033","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1002\/eji.201141676","article-title":"CCL2: a potential prognostic marker and target of anti-inflammatory strategy in HIV\/AIDS pathogenesis","volume":"41","author":"Ansari","year":"2011","journal-title":"Eur J Immunol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924003121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857924003121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:26:03Z","timestamp":1736220363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857924003121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0924857924003121"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107396","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-1 viral decay in blood and semen in antiretroviral-na\u00efve adults initiating dolutegravir\/lamivudine vs. bictegravir\/emtricitabine\/tenofovir alafenamide","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107396"}}